by Amy Berger | Aug 5, 2020 | News, Publications and Press
IITRI is proud to share the promising news of one of our partners, Moleculin! Our team here at IITRI was contracted to perform additional in vitro testing of their drug candidate (WP1122) for antiviral effects against SARS-CoV-2. We used growth medium that more...
by Amy Berger | Mar 19, 2020 | Blog, News
IITRI is now in custody of the a SARS-CoV-2 strain responsible for COVID-19. Our team is working on characterizing the strain for in vitro studies and in vivo modeling to test current vaccines and antivirals in addition to developing new treatments for this...
by iitri | Apr 12, 2019 | News
David McCormick has been selected to present on the development of novel agents to treat sleep-disordered breathing (SDB; sleep apnea) at the invitation-only Science2Startup (S2S)™ symposium on April 23, 2019, in Cambridge. The presenting group of 12 was...
by iitri | Aug 21, 2018 | News
IITRI-Vaccine-Antiinfectives-Lunch-n-Learn Title: Regulatory Approval Pathways for Vaccines and Antivirals: Laying the Groundwork Location: MassBio, 300 Technology Square, 8th Floor, Cambridge MA, 02139 Date/Time: Tuesday, September 25, 2018 Registration: 11 am...
by iitri | Jan 8, 2018 | News
IITRI will be presenting a poster at the ASM Biothreats 2018 Meeting, February 12-14 in Baltimore, MD. For more details, please contact us. Title: Humoral and cellular immune dynamics following Zika virus secondary challenge in non-human primates. Authors: J. M....
by iitri | Sep 5, 2017 | News
Dave McCormick, IITRI’s Director, will be presenting at Eurotox 2017 in a symposium session: Toxicology and Cellular Mechanisms of Electromagnetic Fields (EMF) – Health Aspects of Exposure to EMF Emitted by Wireless Mobile Systems and Emerging Technologies. His...
Recent Comments